NSP NEWS

(Seoul=NSP NEWS AGENCY) = Il Dong Pharmaceutical announced it would supply its cardiovascular active pharmaceutical ingredient (API), Benidipine hydrochloride, to Chinese Guangzhou Tosun Pharmaceutical. The Korean pharmaceutical registered the API and earned sales approval for Benidipine from the Chinese pharmaceutical regulatory authority.

On 22 August, Benidipine’s manufacturer said it signed a partnership agreement on supplying Benidipine with Tosun Pharmaceutical, which specializes in pharmaceutical ingredients and intermediates and went through matters to enter into the Chinese market.

Benidipine is included in the calcium channel blocker (CCB) group to expand blood vessels and relieve the burden on the heart by blocking the calcium ion channels involving blood vessels and cardiac muscle and is mainly used for included in hypertension, angina pectoris treatments, etc. Under the agreement, Il Dong Pharmaceutical would supply their Benidipine hydrochloride to Tosun Pharmaceutical, which would take responsibility for API distribution, sales, and local marketing against the Chinese pharmaceutical market and related companies.